Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

DRD4 48 bp VNTR but not 5-HT2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain

The Pharmacogenomics Journal volume 9, pages 71–77 (2009)Cite this article

Abstract

Weight gain is a major side effect of antipsychotic treatment. The antidopaminergic and antiserotonergic effect of antipsychotics may contribute to antipsychotic-induced weight gain. We, therefore conducted a prospective clinical study, to investigate whether the D4 receptor (DRD4) 48 bp (base pair) variable number of tandem repeat (VNTR) polymorphism and the 5-hydroxytryptamine 2C receptor (HT2C) cysteine for serine substitution at position 23 (Cys23Ser) polymorphism may influence weight gain during antipsychotic treatment in a naturalistic setting of 102 Caucasian psychiatric in-patients. Patients suffering from psychotic disorders and treated according to local clinical practice were classified as either homozygous for the shorter alleles of the DRD4 48 bp VNTR polymorphism (<7-fold repeat, group 1) or heterozygous/homozygous for the long allele (7-fold repeat or higher, group 2). HT2C Cys23Ser polymorphism male patients were grouped hemizygous G (Cys) or C (Ser), while female patients were GG, GC or CC and both sexes were evaluated separately. Concerning the DRD4 48 bp VNTR polymorphism the increase in body mass index was significantly less in group 1 (0.38 kg m−2; s.d.=1.04) than in group 2 (0.89 kg m−2; s.d.=1.23; P=0.003). The difference between the genotype groups remained significant in male patients but not in female patients. In contrast, no influence on antipsychotic-induced increase in body weight was observed for the HT2C Cys23Ser polymorphism. These results support the hypothesis that the DRD4 48 bp VNTR polymorphism influences antipsychotic-induced weight gain. Male patients may be more affected than female patients. Due to the limitations of the study (heterogeneity of treatment, pretreatment and concomitant therapy) further studies are required before diagnostic genotyping of the DRD4 48 bp VNTR polymorphism may be useful for individualizing therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Allison DB, Mentore JL, Heo M, Chander LP, Cappeleri JC, Infante M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–1696.

    CAS  PubMed  Google Scholar 

  2. Stahl SM . Neuropharmacology of obesity: my receptors made me eat it. J Clin Psychiatry 1998; 59: 447–448.

    Article  CAS  PubMed  Google Scholar 

  3. Salomone JD, Correa M, Mingote S, Weber SM . Nucleus accumbens dopamine and the regulation of effort and food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther 2003; 305: 1–8.

    Article  Google Scholar 

  4. Tecott LH, Sun LM, Akana SF . Eating disorder and epilepsy in mice lacking 5-HT2C receptors. Nature 1995; 374: 542–546.

    Article  CAS  PubMed  Google Scholar 

  5. Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepamski K et al. RS-102221: a novel high affinity and selective 5-HT2C receptor antagonist. Neuropharmacology 1997; 36: 621–629.

    Article  CAS  PubMed  Google Scholar 

  6. Nöthen MM, Cichon S, Hemmer S, Hebebrand J, Remschmidt H, Lehmkuhl G et al. Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum Mol Genet 1994; 3: 2207–2212.

    Article  PubMed  Google Scholar 

  7. Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358: 149–152.

    Article  CAS  PubMed  Google Scholar 

  8. Okada M, Northup JK, Ozaki N, Russell JT, Linnoila M, Goldman D . Modification of human 5-HT2C receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution. Mol Psychiatry 2004; 9: 55–64.

    Article  CAS  PubMed  Google Scholar 

  9. Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH et al. Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2C receptor gene (HTR2C). Genomics 1995; 27: 274–279.

    Article  CAS  PubMed  Google Scholar 

  10. Quested DJ, Whale R, Sharpley AL, McGavin CL, Crossland N, Harrison PJ et al. Allelic variation in the 5-HT2C receptor (HTR2C) and functional responses to the 5-HT2C receptor agonist, m-chlorophenylpiperazine. Psychopharmacology 1999; 144: 306–307.

    Article  CAS  PubMed  Google Scholar 

  11. Cohen J . Statistical Power Analysis for Behavioral Sciences (2nd edn). Lawrence Erlbaum: New Jersey, 1988.

    Google Scholar 

  12. Cohen BM, Ennulat DJ, Centorrino F, Matthysse S, Konieczna H, Chu HM et al. Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology 1999; 141: 6–10.

    Article  CAS  PubMed  Google Scholar 

  13. Zalsman G, Frisch A, Lev-Ran S, Martin A, Michaelovsky E, Bensason D et al. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur Neuropsychopharmacol 2003; 13: 183–185.

    Article  CAS  PubMed  Google Scholar 

  14. Rietschel M, Naber D, Fimmers R, Möller HJ, Propping P, Nöthen MM . Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 1997; 8: 1999–2003.

    Article  CAS  PubMed  Google Scholar 

  15. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Liebermann JA, Kennedy JL . Genetic dissection of atypical antipsychotic induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62: 45–66.

    CAS  PubMed  Google Scholar 

  16. Westberg L, Bah J, Rastam M, Gillberg C, Wentz E, Melke J et al. Association between a polymorphism of the 5-HT2C receptor and weight loss in teenage girls. Neuropsychopharmacology 2002; 26: 789–793.

    Article  CAS  PubMed  Google Scholar 

  17. Hu X, Giotakis O, Li T, Karwautz A, Treasure J, Collier DA . Association of the 5-HT2C gene with susceptability and minimum body mass index in anorexia nervosa. Neuroreport 2003; 14: 781–783.

    Article  CAS  PubMed  Google Scholar 

  18. Praschak-Rieder N, Willeit M, Zill P, Winkler D, Thierry N, Konstantinidis A et al. A Cys23-Ser23 substitution in the 5-HT2C receptor gene influences body weight regulation in females with seasonal affective disorder: an Australian-Canadian collaborative study. J Psychiatr Res 2005; 39: 561–567.

    Article  PubMed  Google Scholar 

  19. Reynolds GP, Zhang ZJ, Zhang XB . Association of antipsychotic induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086–2087.

    Article  CAS  PubMed  Google Scholar 

  20. Reynolds GP, Zhang ZJ, Zhang XB . Polymorphism of the promotor region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003; 160: 677–679.

    Article  PubMed  Google Scholar 

  21. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F et al. Weight gain associated with the −759 C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 76–78.

    Article  Google Scholar 

  22. Templeman LA, Reynolds GP, Arranz B, San L . Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005; 15: 195–200.

    Article  CAS  PubMed  Google Scholar 

  23. Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt S . Clozapine-induced weight gain associated with the 5HT2C receptor −759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005; 133: 97–100.

    Article  Google Scholar 

  24. Reynolds GP, Hill MJ, Kirk SL . The 5-HT2C receptor and antipsychotic-induced weight gain-mechanisms and genetics. J Psychopharmacol 2006; 20: 15–18.

    Article  PubMed  Google Scholar 

  25. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL . Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007; 10: 697–704.

    Article  CAS  PubMed  Google Scholar 

  26. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD . Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001; 62: 231–238.

    Article  CAS  PubMed  Google Scholar 

  27. Briffa D, Meehan T . Weight changes during clozapine treatment. Aust NZ J Psychiatry 1998; 32: 718–721.

    Article  CAS  Google Scholar 

  28. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002; 41: 337–343.

    Article  PubMed  Google Scholar 

  29. Blin O, Micallef J . Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry 2001; 62: 11–21.

    CAS  PubMed  Google Scholar 

  30. Halbreich U, Kahn LS . Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology 2003; 28: 1–16.

    CAS  PubMed  Google Scholar 

  31. Li MD, Parker SL, Kane JK . Regulation of feeding-associated peptides and receptors by nicotine. Mol Neurobiol 2000; 22: 143–165.

    Article  CAS  PubMed  Google Scholar 

  32. Frankenburg FR, Zanarini MC, Kando J, Centorrino F . Clozapine and body mass change. Biol Psychiatry 1998; 43: 520–524.

    Article  CAS  PubMed  Google Scholar 

  33. Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ . Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001; 62: 41–44.

    Article  CAS  PubMed  Google Scholar 

  34. Kalow W, Tang BW . Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991; 49: 44–48.

    Article  CAS  PubMed  Google Scholar 

  35. Levitan RD, Masellis M, Basile V, Lam RW, Kaplan AS, Davis C et al. The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective. Biol Psychiatry 2004; 56: 665–669.

    Article  CAS  PubMed  Google Scholar 

  36. Ebstein RP . The molecular genetic architecture of human personality: beyond self-report questionares. Mol Psychiatry 2006; 11: 427–445.

    Article  CAS  PubMed  Google Scholar 

  37. Wirshing DA, Wirshing DC, Kysar L, Berisford MA, Goldstein D, Pashdag J et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358–363.

    Article  CAS  PubMed  Google Scholar 

  38. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M . Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149: 68–72.

    Article  CAS  PubMed  Google Scholar 

  39. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S . Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005; 25: 255–258.

    Article  CAS  PubMed  Google Scholar 

  40. Bondy B, Spellmann I . Pharmacogenetics of antipsychotics: useful for the clinician? Curr Opin Psychiatry 2007; 20: 126–130.

    Article  PubMed  Google Scholar 

  41. Rietschel M, Naber D, Oberlander H, Holzbach R, Fimmers R, Eggermann K et al. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 1996; 15: 491–496.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

    J Popp & W Steimer

  2. Psychiatrische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

    S Leucht & S Heres

Authors
  1. J Popp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Leucht
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Heres
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Steimer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W Steimer.

Additional information

Duality of Interest

None declared.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Popp, J., Leucht, S., Heres, S. et al. DRD4 48 bp VNTR but not 5-HT2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J 9, 71–77 (2009). https://doi.org/10.1038/tpj.2008.5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2008.5

Keywords

This article is cited by

Search

Advanced search

Quick links